Health News

Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL.

Read more

Filed under: Pharmacy News
Tags: cancer, Oncology, Pharmacy, Prostate Cancer

Related posts

• ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011 (0)
  Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM announces darinaparsin preclinical data on prostate cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San [...]
  
  
• Study Of Investigational Agent Abiraterone Acetate For Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria (0)
  Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc... Read more [tags] Pharmacy News [/tags]
  
  
• Scientists study a botanical formula that kills aggressive prostate cancer tumors (0)
  Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology. Read more [tags] Pharmacy News [/tags]
  
  
• Poniard Pharmaceuticals’ picoplatin Phase 2 study in metastatic CRPC: Positive results (0)
  Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today [...]